## Roberto Civitelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9132900/publications.pdf

Version: 2024-02-01

186 papers 11,377 citations

63 h-index 101 g-index

194 all docs

194 docs citations

times ranked

194

8536 citing authors

#	Article	IF	Citations
1	The Association of Pelvic Bone Mineral Density and with Proximal Femoral and Spine Bone Mineral Density in Post-menopausal Women. Journal of Clinical Densitometry, 2022, , .	1.2	1
2	Effect of peripheral neuropathy on bone mineral density in adults with diabetes: A systematic review of the literature and meta-analysis. Bone, 2021, 147, 115932.	2.9	8
3	N-cadherin in osteolineage cells modulates stromal support of tumor growth. Journal of Bone Oncology, 2021, 28, 100356.	2.4	O
4	Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience. Journal of the Endocrine Society, 2021, 5, bvab099.	0.2	18
5	Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. Journal of Bone and Mineral Research, 2021, 36, 2139-2152.	2.8	35
6	Calcitonin in osteoporosis., 2021,, 1771-1790.		0
7	Intercellular junctions and cell–cell communication in the skeletal system. , 2020, , 423-442.		6
8	<i>ATRAID</i> regulates the action of nitrogen-containing bisphosphonates on bone. Science Translational Medicine, 2020, 12, .	12.4	15
9	Scientific Editing in the <scp>COVID</scp> â€19 Era—Personal Vignettes from the <scp><i>JBMR</i></scp> Editors. Journal of Bone and Mineral Research, 2020, 35, 1005-1008.	2.8	2
10	Connexin 43 Is Necessary for Murine Tendon Enthesis Formation and Response to Loading. Journal of Bone and Mineral Research, 2020, 35, 1494-1503.	2.8	11
11	Gain-of-Function Lrp5 Mutation Improves Bone Mass and Strength and Delays Hyperglycemia in a Mouse Model of Insulin-Deficient Diabetes. Journal of Bone and Mineral Research, 2020, 36, 1403-1415.	2.8	13
12	Osterix-Cre marks distinct subsets of CD45- and CD45+ stromal populations in extra-skeletal tumors with pro-tumorigenic characteristics. ELife, 2020, 9, .	6.0	11
13	Unsung Heroes of Research Integrity. Journal of Bone and Mineral Research, 2020, 36, 2287-2289.	2.8	2
14	New Guidelines for Data Reporting and Statistical Analysis: Helping Authors With Transparency and Rigor in Research. Journal of Bone and Mineral Research, 2019, 34, 1981-1984.	2.8	7
15	Changing of the Guard. Journal of Bone and Mineral Research, 2018, 33, 3-4.	2.8	О
16	The Rise of Research Integrity: Everyone Will Play a Role. Journal of Bone and Mineral Research, 2018, 33, 1914-1915.	2.8	3
17	Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice. PLoS Biology, 2018, 16, e3000047.	5.6	110
18	Focusing on the Science: <i>JBMR</i> Manuscript Types. Journal of Bone and Mineral Research, 2018, 33, 1556-1557.	2.8	0

#	Article	IF	CITATIONS
19	Sclerostin Resistance Protects Bone Mass and Retards the Onset of Metabolic Abnormalities in a Mouse Model of Type 1 Diabetes. Diabetes, 2018, 67, 1701-P.	0.6	8
20	Relationship Between Low Bone Mineral Density and Fractures With Incident Cardiovascular Disease: A Systematic Review and Meta-Analysis. Journal of Bone and Mineral Research, 2017, 32, 1126-1135.	2.8	109
21	Nâ€cadherin Regulation of Bone Growth and Homeostasis Is Osteolineage Stage–Specific. Journal of Bone and Mineral Research, 2017, 32, 1332-1342.	2.8	19
22	Bone Turnover with Venlafaxine Treatment in Older Adults with Depression. Journal of the American Geriatrics Society, 2017, 65, 2057-2063.	2.6	14
23	Bone Mineral Density and Risk of Heart Failure in Older Adults: The Cardiovascular Health Study. Journal of the American Heart Association, 2017, 6, .	3.7	24
24	Toward personalized calcium and vitamin D supplementation. American Journal of Clinical Nutrition, 2017, 105, 777-778.	4.7	0
25	Bone matrix components activate the NLRP3 inflammasome and promote osteoclast differentiation. Scientific Reports, 2017, 7, 6630.	3.3	63
26	Chronic inflammation triggered by the NLRP3 inflammasome in myeloid cells promotes growth plate dysplasia by mesenchymal cells. Scientific Reports, 2017, 7, 4880.	3.3	22
27	Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma. Clinical Cancer Research, 2017, 23, 416-429.	7.0	10
28	Heterozygous deletion of both sclerostin (Sost) and connexin43 (Gja1) genes in mice is not sufficient to impair cortical bone modeling. PLoS ONE, 2017, 12, e0187980.	2.5	6
29	A Functional Assay to Assess Connexin 43-Mediated Cell-to-Cell Communication of Second Messengers in Cultured Bone Cells. Methods in Molecular Biology, 2016, 1437, 193-201.	0.9	5
30	Skeletal Metabolism, Fracture Risk, and Fracture Outcomes in Type 1 and Type 2 Diabetes. Diabetes, 2016, 65, 1757-1766.	0.6	132
31	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clinical and Experimental Research, 2016, 28, 1-16.	2.9	22
32	Connexins in the skeleton. Seminars in Cell and Developmental Biology, 2016, 50, 31-39.	5.0	50
33	N-cadherin Restrains PTH Activation of Lrp6 $\hat{\mathbb{I}}^2$ -catenin Signaling and Osteoanabolic Action. Journal of Bone and Mineral Research, 2015, 30, 274-285.	2.8	37
34	Molecular Actions of Parathyroid Hormone. , 2015, , 119-126.		2
35	NLRP3 mediates osteolysis through inflammationâ€dependent and â€independent mechanisms. FASEB Journal, 2015, 29, 1269-1279.	0.5	58
36	Deletion of Connexin43 in Osteoblasts/Osteocytes Leads to Impaired Muscle Formation in Mice. Journal of Bone and Mineral Research, 2015, 30, 596-605.	2.8	79

#	Article	IF	CITATIONS
37	Loss of TGF-Î <sup>2</sup> Signaling in Bone Marrow Mesenchymal Progenitors Promotes Adipocyte over Osteoblast Differentiation but Does Not Disrupt the HSC Niche. Blood, 2015, 126, 666-666.	1.4	O
38	p62 Is Required for Stem Cell/Progenitor Retention through Inhibition of IKK/NF-κB/Ccl4 Signaling at the Bone Marrow Macrophage-Osteoblast Niche. Cell Reports, 2014, 9, 2084-2097.	6.4	56
39	Cell–Cell Signaling: Broadening Our View of the Basic Multicellular Unit. Calcified Tissue International, 2014, 94, 2-3.	3.1	14
40	Molecular Mechanisms of Osteoblast/Osteocyte Regulation by Connexin43. Calcified Tissue International, 2014, 94, 55-67.	3.1	52
41	Cadherin-Mediated Cell–Cell Adhesion and Signaling in the Skeleton. Calcified Tissue International, 2014, 94, 46-54.	3.1	75
42	Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. World Journal of Biological Psychiatry, 2014, 15, 404-410.	2.6	17
43	Depression, Antidepressants, and Bone Health in Older Adults: A Systematic Review. Journal of the American Geriatrics Society, 2014, 62, 1434-1441.	2.6	43
44	Serotoninâ€"norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption. Osteoporosis International, 2013, 24, 1741-1749.	3.1	38
45	Postnatal Ablation of Osteoblast <i>Smad4</i> Enhances Proliferative Responses to Canonical Wnt Signaling via Interactions with β-catenin. Journal of Cell Science, 2013, 126, 5598-609.	2.0	23
46	Risedronate increases osteoblastic differentiation and function through connexin43. Biochemical and Biophysical Research Communications, 2013, 432, 152-156.	2.1	18
47	Genetic variation in the serotonin transporter and serotonin 1B receptor predicts reduced bone formation during serotonin-reuptake inhibitor treatment in older adults. American Journal of Geriatric Psychiatry, 2013, 21, S157-S158.	1.2	0
48	Casting New Light on the Sunshine Vitamin. Calcified Tissue International, 2013, 92, 75-76.	3.1	0
49	Connexin43 modulates post-natal cortical bone modeling and mechano-responsiveness. BoneKEy Reports, 2013, 2, 446.	2.7	17
50	Embryonic ablation of osteoblast <i>Smad4</i> interrupts matrix synthesis in response to canonical wnt signaling and causes an osteogenesis imperfecta-like phenotype. Journal of Cell Science, 2013, 126, 4974-84.	2.0	36
51	Calcitonin in Osteoporosis., 2013,, 1839-1858.		0
52	Connexin-43 in the osteogenic BM niche regulates its cellular composition and the bidirectional traffic of hematopoietic stem cells and progenitors. Blood, 2012, 119, 5144-5154.	1.4	82
53	N-cadherin in osteolineage cells is not required for maintenance of hematopoietic stem cells. Blood, 2012, 120, 295-302.	1.4	80
54	Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. Blood, 2012, 120, 303-313.	1.4	81

#	Article	IF	CITATIONS
55	Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice. Bone, 2012, 51, 787-794.	2.9	37
56	Tibial Loading Increases Osteogenic Gene Expression and Cortical Bone Volume in Mature and Middle-Aged Mice. PLoS ONE, 2012, 7, e34980.	2.5	54
57	Constitutively Activated NLRP3 Inflammasome Causes Inflammation and Abnormal Skeletal Development in Mice. PLoS ONE, 2012, 7, e35979.	2.5	105
58	Enhanced Periosteal and Endocortical Responses to Axial Tibial Compression Loading in Conditional Connexin43 Deficient Mice. PLoS ONE, 2012, 7, e44222.	2.5	66
59	Oneâ€Year Effects of Vitamin D and Calcium Supplementation on Chronic Periodontitis. Journal of Periodontology, 2011, 82, 25-32.	3.4	147
60	Lowâ€magnitude wholeâ€body vibration does not enhance the anabolic skeletal effects of intermittent PTH in adult mice. Journal of Orthopaedic Research, 2011, 29, 465-472.	2.3	23
61	Connexin43 deficiency reduces the sensitivity of cortical bone to the effects of muscle paralysis. Journal of Bone and Mineral Research, 2011, 26, 2151-2160.	2.8	70
62	Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Molecular Biology of the Cell, 2011, 22, 1240-1251.	2.1	128
63	N-cadherin and cadherin 11 modulate postnatal bone growth and osteoblast differentiation by distinct mechanisms. Journal of Cell Science, 2010, 123, 2640-2648.	2.0	100
64	Microfibril-associated Glycoprotein-1, an Extracellular Matrix Regulator of Bone Remodeling. Journal of Biological Chemistry, 2010, 285, 23858-23867.	3.4	26
65	Patient Satisfaction in Postmenopausal Women Treated with a Weekly Bisphosphonate Transitioned to Once-Monthly Ibandronate. Journal of Women's Health, 2009, 18, 935-943.	3.3	16
66	Calcium and vitamin D use among adults in periodontal disease maintenance programmes. British Dental Journal, 2009, 206, 627-631.	0.6	29
67	Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series. Calcified Tissue International, 2009, 85, 37-44.	3.1	105
68	Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporosis International, 2009, 20, 843-851.	3.1	163
69	Crossâ€Sectional Study of Vitamin D and Calcium Supplementation Effects on Chronic Periodontitis. Journal of Periodontology, 2009, 80, 1433-1439.	3.4	131
70	Alveolar bone measurement precision for phosphor-plate images. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2009, 108, e96-e107.	1.4	6
71	Connexins in Skeletal Biology. , 2009, , 371-386.		1
72	Connexin-43 Regulates the Cell Cycle Entry of Hematopoietic Stem Cells within the Stem Cell Niche Blood, 2009, 114, 1500-1500.	1.4	0

#	Article	IF	CITATIONS
73	The proâ€osteogenic action of βâ€catenin requires interaction with BMP signaling, but not Tcf/Lef transcriptional activity. Journal of Cellular Biochemistry, 2008, 104, 942-952.	2.6	10
74	Attenuated Response to In Vivo Mechanical Loading in Mice With Conditional Osteoblast Ablation of the Connexin43 Gene ( <i>Gja1</i> ). Journal of Bone and Mineral Research, 2008, 23, 879-886.	2.8	106
75	Connexin43 Modulation of Osteoblast/Osteocyte Apoptosis: A Potential Therapeutic Target?. Journal of Bone and Mineral Research, 2008, 23, 1709-1711.	2.8	14
76	Cell–cell communication in the osteoblast/osteocyte lineage. Archives of Biochemistry and Biophysics, 2008, 473, 188-192.	3.0	227
77	The conditional connexin43G138R mouse mutant represents a new model of hereditary oculodentodigital dysplasia in humans. Human Molecular Genetics, 2008, 17, 539-554.	2.9	157
78	Intercellular Junctions and Cell–Cell Communication in the Skeletal System. , 2008, , 425-445.		3
79	Calcitonin in Osteoporosis. , 2008, , 1743-1765.		0
80	Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Journal of Rheumatology, 2008, 35, 488-97.	2.0	99
81	Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenetics and Genomics, 2007, 17, 555-567.	1.5	92
82	Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis. Drug Safety, 2007, 30, 755-763.	3.2	111
83	Effects of dietary calcium compared with calcium supplements on estrogen metabolism and bone mineral density. American Journal of Clinical Nutrition, 2007, 85, 1428-1433.	4.7	40
84	Bone Loss after Temporarily Induced Muscle Paralysis by Botox Is Not Fully Recovered After 12 Weeks. Annals of the New York Academy of Sciences, 2007, 1116, 444-460.	3.8	66
85	Maintaining the Trust of Physicians and the Public in the Medical Literature: Report of a Task Force on Scientific Publishing of Clinical Trials. Journal of Bone and Mineral Research, 2007, 22, 1661-1667.	2.8	6
86	Use of intravenous bisphosphonates in osteoporosis. Current Osteoporosis Reports, 2007, 5, 8-13.	3.6	13
87	Role of Connexin43 in Osteoblast Response to Physical Load. Annals of the New York Academy of Sciences, 2006, 1068, 214-224.	3.8	40
88	Perspective: Cell-Cell Adhesion and Signaling Through Cadherins: Connecting Bone Cells in Their Microenvironment. Journal of Bone and Mineral Research, 2006, 21, 1821-1827.	2.8	61
89	Accentuated Ovariectomy-Induced Bone Loss and Altered Osteogenesis in Heterozygous N-Cadherin Null Mice. Journal of Bone and Mineral Research, 2006, 21, 1897-1906.	2.8	36
90	A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporosis International, 2006, 17, 159-166.	3.1	33

#	Article	IF	CITATIONS
91	Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis and Rheumatism, 2006, 54, 1838-1846.	6.7	240
92	Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. Journal of Cell Science, 2006, 119, 4187-4198.	2.0	161
93	Heterogeneous nuclear ribonucleoprotein K represses transcription from a cytosine/thymidine-rich element in the osteocalcin promoter. Biochemical Journal, 2005, 385, 613-623.	3.7	28
94	A New Selective Estrogen Receptor Modulator, CHF 4227.01, Preserves Bone Mass and Microarchitecture in Ovariectomized Rats. Journal of Bone and Mineral Research, 2005, 20, 2178-2188.	2.8	20
95	Dominant Negative N-Cadherin Inhibits Osteoclast Differentiation by Interfering With $\hat{l}^2$ -Catenin Regulation of RANKL, Independent of Cell-Cell Adhesion. Journal of Bone and Mineral Research, 2005, 20, 2200-2212.	2.8	24
96	?-Catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. Journal of Cellular Biochemistry, 2005, 94, 403-418.	2.6	203
97	Cellâ€cell interactions in regulating osteogenesis and osteoblast function. Birth Defects Research Part C: Embryo Today Reviews, 2005, 75, 72-80.	3.6	84
98	Gap Junctions Regulate Extracellular Signal-regulated Kinase Signaling to Affect Gene Transcription. Molecular Biology of the Cell, 2005, 16, 64-72.	2.1	114
99	Increased Prevalence of Celiac Disease and Need for Routine Screening Among Patients With Osteoporosis. Archives of Internal Medicine, 2005, 165, 393.	3.8	137
100	Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass. Archives of Internal Medicine, 2005, 165, 1762.	3.8	385
101	Gap junctions in skeletal development and function. Biochimica Et Biophysica Acta - Biomembranes, 2005, 1719, 69-81.	2.6	125
102	Cell-to-cell interactions in bone. Biochemical and Biophysical Research Communications, 2005, 328, 721-727.	2.1	101
103	Targeted expression of a dominant-negative N-cadherin in vivo delays peak bone mass and increases adipogenesis. Journal of Cell Science, 2004, 117, 2853-2864.	2.0	97
104	Interactions of Amelogenins with Octacalcium Phosphate Crystal Faces Are Dose Dependent. Calcified Tissue International, 2004, 74, 522-531.	3.1	55
105	Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis. Calcified Tissue International, 2004, 74, 129-135.	3.1	211
106	Estrogen and/or Calcium Plus Vitamin D Increase Mandibular Bone Mass. Journal of Periodontology, 2004, 75, 811-816.	3.4	37
107	The oxidative metabolism of estrogen modulates response to ERT/HRT in postmenopausal women. Bone, 2004, 35, 682-688.	2.9	14
108	Dexamethasone, BMP-2, and 1,25-dihydroxyvitamin D enhance a more differentiated osteoblast phenotype: validation of an in vitro model for human bone marrow-derived primary osteoblasts. Steroids, 2004, 69, 219-226.	1.8	154

#	Article	IF	CITATIONS
109	Genomic approaches to identifying transcriptional regulators of osteoblast differentiation. Genome Biology, 2003, 4, 222.	9.6	35
110	Development of Mice with Osteoblast-Specific Connexin43 Gene Deletion. Cell Communication and Adhesion, 2003, 10, 445-450.	1.0	37
111	Activation of L-type Calcium Channels Is Required for Gap Junction-mediated Intercellular Calcium Signaling in Osteoblastic Cells. Journal of Biological Chemistry, 2003, 278, 4082-4086.	3.4	74
112	Gap Junctional Communication Modulates Gene Transcription by Altering the Recruitment of Sp1 and Sp3 to Connexin-response Elements in Osteoblast Promoters. Journal of Biological Chemistry, 2003, 278, 24377-24387.	3.4	121
113	Alveolar and Postcranial Bone Density in Postmenopausal Women Receiving Hormone/Estrogen Replacement Therapy. Archives of Internal Medicine, 2002, 162, 1409.	3.8	74
114	The Pattern of Alveolar Crest Height Change in Healthy Postmenopausal Women After 3 Years of Hormone/Estrogen Replacement Therapy. Journal of Periodontology, 2002, 73, 1279-1284.	3.4	29
115	Intercellular Calcium Signaling Occurs between Human Osteoblasts and Osteoclasts and Requires Activation of Osteoclast P2X7 Receptors. Journal of Biological Chemistry, 2002, 277, 7574-7580.	3.4	134
116	Relationships Between Clinical Attachment Level and Spine and Hip Bone Mineral Density: Data From Healthy Postmenopausal Women. Journal of Periodontology, 2002, 73, 298-301.	3.4	58
117	"In Memoriam." Carlo Gennari, M.D. (July 27, 1932-August 6, 2002). Calcified Tissue International, 2002, 71, 463-464.	3.1	0
118	Intercellular Junctions and Cell-Cell Communication in Bone. , 2002, , 287-302.		3
119	Intercellular Junctions and Cell-Cell Communication in Bone. , 2002, , 287-302.		2
120	Connexin45 Interacts with Zonula Occludens-1 in Osteoblastic Cells. Cell Communication and Adhesion, 2001, 8, 209-212.	1.0	20
121	P2-mediated responses in osteoclasts and osteoclast-like cells. Drug Development Research, 2001, 53, 126-129.	2.9	6
122	Sequence and Structure of the Mouse Connexin45 Gene. Bioscience Reports, 2001, 21, 683-689.	2.4	12
123	Proliferation, Differentiation and Apoptosis in Connexin43-Null Osteoblasts. Cell Communication and Adhesion, 2001, 8, 367-371.	1.0	42
124	Connexin45 Interacts with Zonula Occludens-1 and Connexin43 in Osteoblastic Cells. Journal of Biological Chemistry, 2001, 276, 23051-23055.	3.4	97
125	Calcitonin for Treatment of Osteoporosis. , 2001, , 651-673.		0
126	Connexin43 Deficiency Causes Delayed Ossification, Craniofacial Abnormalities, and Osteoblast Dysfunction. Journal of Cell Biology, 2000, 151, 931-944.	5.2	357

#	Article	IF	CITATIONS
127	Regulation of ?V?3 and ?V?5 integrins by dexamethasone in normal human osteoblastic cells. , 2000, 77, 265-276.		65
128	Differential regulation of cadherins by dexamethasone in human osteoblastic cells., 2000, 77, 499-506.		35
129	Relative abundance of different cadherins defines differentiation of mesenchymal precursors into osteogenic, myogenic, or adipogenic pathways. Journal of Cellular Biochemistry, 2000, 78, 566-577.	2.6	86
130	A Dominant Negative Cadherin Inhibits Osteoblast Differentiation. Journal of Bone and Mineral Research, 2000, 15, 2362-2370.	2.8	69
131	The Oxidative Metabolism of Estradiol Conditions Postmenopausal Bone Density and Bone Loss. Journal of Bone and Mineral Research, 2000, 15, 2513-2520.	2.8	35
132	Human Osteoblastic Cells Propagate Intercellular Calcium Signals by Two Different Mechanisms. Journal of Bone and Mineral Research, 2000, 15, 1024-1032.	2.8	100
133	Dawning of a New Era at CTI. Calcified Tissue International, 2000, 67, 1-1.	3.1	0
134	Comparison of Morphological Measurements Extracted From Digitized Dental Radiographs With Lumbar and Femoral Bone Mineral Density Measurements in Postmenopausal Women. Journal of Periodontology, 2000, 71, 335-340.	3.4	35
135	Alveolar Bone Height and Postcranial Bone Mineral Density: Negative Effects of Cigarette Smoking and Parity. Journal of Periodontology, 2000, 71, 683-689.	3.4	28
136	Relative abundance of different cadherins defines differentiation of mesenchymal precursors into osteogenic, myogenic, or adipogenic pathways. Journal of Cellular Biochemistry, 2000, 78, 566-577.	2.6	3
137	Osteoblast–osteoclast communication. Current Opinion in Orthopaedics, 1999, 10, 367-373.	0.3	3
138	Cyclic Stretch Enhances Gap Junctional Communication Between Osteoblastic Cells. Journal of Bone and Mineral Research, 1998, 13, 218-228.	2.8	157
139	Human Osteoblasts Express a Repertoire of Cadherins, Which Are Critical for BMP-2-Induced Osteogenic Differentiation. Journal of Bone and Mineral Research, 1998, 13, 633-644.	2.8	146
140	Regulation of connexin43 expression and function by prostaglandin E2 (PGE2) and parathyroid hormone (PTH) in osteoblastic cells. Journal of Cellular Biochemistry, 1998, 68, 8-21.	2.6	107
141	Age-Related Decline of Bone Mass and Intestinal Calcium Absorption in Normal Males. Calcified Tissue International, 1998, 63, 197-201.	3.1	40
142	Impaired intramembranous bone formation in connexin43 null mice. Bone, 1998, 23, S149-S653.	2.9	13
143	Gap Junctional Communication Modulates Gene Expression in Osteoblastic Cells. Molecular Biology of the Cell, 1998, 9, 2249-2258.	2.1	238
144	Cell-Cell Communication in Bone. Advances in Organ Biology, 1998, , 543-564.	0.1	2

#	Article	IF	CITATIONS
145	Does vitamin D receptor gene polymorphism affect bone mineral density and calcium absorption?. Current Opinion in Gastroenterology, 1998, 14, 164-172.	2.3	4
146	Pathophysiology of Calcium, Phosphate, and Magnesium Absorption. , 1998, , 165-205.		2
147	ATP- and Gap Junction–dependent Intercellular Calcium Signaling in Osteoblastic Cells. Journal of Cell Biology, 1997, 139, 497-506.	5.2	242
148	Attachment loss with postmenopausal age and smoking. Journal of Periodontal Research, 1997, 32, 619-625.	2.7	64
149	An Intact N Terminus Is Required for the Anabolic Action of Parathyroid Hormone on Adult Female Rats. Journal of Bone and Mineral Research, 1997, 12, 384-392.	2.8	48
150	In Vitro and In Vivo effects of ipriflavone on bone formation and bone biomechanics. Calcified Tissue International, 1997, 61, S12-S14.	3.1	56
151	Intake and absorption of mineral nutrients. Current Opinion in Gastroenterology, 1996, 12, 190-198.	2.3	1
152	Application of Fluorescence Techniques to Bone Biology. , 1996, , 131-156.		0
153	Bone density in white Brazilian women: Rapid loss at the time around the menopause. Calcified Tissue International, 1995, 56, 186-191.	3.1	36
154	Ipriflavone improves bone density and biomechanical properties of adult male rat bones. Calcified Tissue International, 1995, 56, 215-219.	3.1	38
155	The role of vitamin D metabolites in the treatment of osteoporosis. Calcified Tissue International, 1995, 57, 409-414.	3.1	16
156	Cell-Cell Communication in Bone. Calcified Tissue International, 1995, 56, S29-S31.	3.1	36
157	Transfected connexin45 alters gap junction permeability in cells expressing endogenous connexin43 Journal of Cell Biology, 1995, 130, 987-995.	<b>5.</b> 2	160
158	Estrogen action on the bone mass of postmenopausal women is dependent on body mass and initial bone density. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 776-782.	3.6	23
159	Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcified Tissue International, 1994, 55, 356-362.	3.1	69
160	Single-cell analysis of cyclic AMP response to parathyroid hormone in osteoblastic cells. Journal of Bone and Mineral Research, 1994, 9, 1407-1417.	2.8	28
161	Estrogen status and bone mass in the premenopausal period: Is osteoporosis a developmental disease?. Journal of Endocrinological Investigation, 1993, 16, 829-839.	3.3	4
162	Connexin43 mediates direct intercellular communication in human osteoblastic cell networks Journal of Clinical Investigation, 1993, 91, 1888-1896.	8.2	210

#	Article	IF	CITATIONS
163	An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcified Tissue International, 1992, 50, 381-383.	3.1	77
164	Effect of estrogen and calcitonin on vertebral bone density and vertebral height in osteoporotic women. Osteoporosis International, 1992, 2, 70-73.	3.1	10
165	Estrogen status and heredity are major determinants of premenopausal bone mass Journal of Clinical Investigation, 1992, 90, 2464-2471.	8.2	127
166	Monitoring cytosolic calcium in parathyroid hormone target cells: Osteoblasts and renal epithelia. Cytotechnology, 1991, 13, 217-227.	0.3	5
167	Is there an effective treatment for glucocorticoid-induced osteoporosis?. Calcified Tissue International, 1991, 49, 141-142.	3.1	16
168	Subclinical Vitamin D Deficiency in Postmenopausal Women with Low Vertebral Bone Mass*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 628-634.	3.6	259
169	Dissociation of Second Messenger Activation by Parathyroid Hormone Fragments in Osteosarcoma Cells*. Endocrinology, 1991, 128, 3032-3039.	2.8	91
170	Parathyroid Hormone Receptor Coupling to Phospholipase C is an Alternate Pathway of Signal Transduction in the Bone and Kidney., 1991,, 1499-1508.		0
171	Cyclic AMP-dependent and calcium-dependent signals in parathyroid hormone function. Experimental Gerontology, 1990, 25, 223-231.	2.8	23
172	Biological activity of different calcitonins in men. Experimental Gerontology, 1990, 25, 339-347.	2.8	13
173	Estrogen Preserves a Normal Intestinal Responsiveness to 1,25-Dihydroxyvitamin D <sub>3</sub> in Oophorectomized Women*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 1288-1293.	3.6	233
174	Nongenomic Activation of the Calcium Message System by Vitamin D Metabolites in Osteoblast-like Cells. Endocrinology, 1990, 127, 2253-2262.	2.8	175
175	Calcitonin and estrogens. Journal of Endocrinological Investigation, 1990, 13, 625-630.	3.3	14
176	Second Messenger Signaling in the Regulation of Collagenase Production by Osteogenic Sarcoma Cells*. Endocrinology, 1989, 124, 2928-2934.	2.8	64
177	Parathyroid Hormone-Related Peptide Transiently Increases Cytosolic Calcium in Osteoblast-Like Cells: Comparison with Parathyroid Hormone*. Endocrinology, 1989, 125, 1204-1210.	2.8	87
178	Effect of L-lysine on cytosolic calcium homeostasis in cultured human normal fibroblasts. Calcified Tissue International, 1989, 45, 193-197.	3.1	4
179	A dihydropyridine-sensitive calcium channel in rodent osteoblastic cells. Calcified Tissue International, 1989, 45, 54-57.	3.1	30
180	Central osteosclerosis with ectodermal dysplasia: Clinical, laboratory, radiologic, and histopathologic characterization with review of the literature. Journal of Bone and Mineral Research, 1989, 4, 863-875.	2.8	17

#	Article	IF	CITATION
181	Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxyvitamin D-1 $\hat{1}$ ±-hydroxylase reserve in postmenopausal osteoporosis. Calcified Tissue International, 1988, 42, 77-86.	3.1	153
182	Does Interleukin-1 affect intracellular calcium in osteoblast-like cells (UMR-106)?. Journal of Bone and Mineral Research, 1988, 3, 107-112.	2.8	16
183	Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment Journal of Clinical Investigation, 1988, 82, 1268-1274.	8.2	333
184	Membrane potential and cation content of osteoblast-like cells (UMR 106) assessed by fluorescent dyes. Journal of Cellular Physiology, 1987, 131, 434-441.	4.1	34
185	Cytoplasmic pH regulation in canine renal proximal tubule cells. Kidney International, 1987, 31, 1113-1120.	5.2	16
186	Stimulation of inositol trisphosphate and diacylglycerol production in renal tubular cells by parathyroid hormone Journal of Clinical Investigation, 1987, 79, 230-239.	8.2	228